We are live on ! Find out more
MPM Asset Management

MPM Asset Management Portfolio holdings

AUM $44.5M Turnover 20%
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+8.83%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$308M
AUM Growth
-$14.4M
Cap. Flow
-$7.25M
Cap. Flow %
-2.35%
Top 10 Hldgs %
99.87%
Holding
15
New
–
Increased
1
Reduced
1
Closed
1
Avg Time Held
1.9 years
Top 10 Avg Time Held
1.5 years
Top 20 Avg Time Held
1.9 years

Top Buys

Rank Stock Value
1
CHMA
Chiasma
CHMA
+$241K

Top Sells

Rank Stock Value
1
NVRO icon
Nevro
NVRO
+$5.27M
2
AVTX icon
Avalo Therapeutics
AVTX
+$2.22M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
RDUS icon
1
DELISTED
Radius Health
RDUS
$214M 69.51%
5,831,253
– –
2014 Q2
8 quarters
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$822M
$21.4M 6.93%
2,168,691
– –
2016 Q1
1 quarter
EPZM
3
DELISTED
Epizyme
EPZM
$17.7M 5.75%
1,729,674
– –
2013 Q2
12 quarters
CHMA
4
DELISTED
Chiasma
CHMA
$16.6M 5.38%
5,736,296
+54,752
+1% +$241K
2015 Q3
3 quarters
ELGX
5
DELISTED
Endologix
ELGX
$14M 4.53%
112,145
– –
2016 Q1
1 quarter
TARA icon
6
Protara Therapeutics
TARA
$148M
$7.9M 2.56%
24,585
– –
2014 Q4
6 quarters
PETX
7
DELISTED
Aratana Therapeutics
PETX
$7.06M 2.29%
1,117,875
– –
2013 Q2
12 quarters
NVRO icon
8
DELISTED
Nevro
NVRO
$5.34M 1.73%
72,413
-77,587
-52% -$5.27M
2014 Q4
6 quarters
HSTO
9
DELISTED
Histogen
HSTO
$2.46M 0.8%
5,960
– –
2013 Q3
11 quarters
SVRA icon
10
Savara
SVRA
$1.15B
$1.2M 0.39%
36,455
– –
2014 Q1
9 quarters
CLCD
11
DELISTED
CoLucid Pharmaceuticals
CLCD
$178K 0.06%
21,806
– –
2015 Q2
4 quarters
SGMO icon
12
DELISTED
Sangamo Therapeutics
SGMO
$130K 0.04%
22,487
– –
2013 Q4
10 quarters
MGNX icon
13
MacroGenics
MGNX
$127M
$86K 0.03%
3,168
– –
2013 Q4
10 quarters
ETRM
14
DELISTED
EnteroMedics
ETRM
$22K 0.01%
1,060
– –
2013 Q2
12 quarters
AVTX icon
15
Avalo Therapeutics
AVTX
$390M
– –
-207
Closed -$2.22M –

Similar funds

MPM Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, MPM Asset Management held 15 positions worth $308M, down 4.5% from $323M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM Asset Management's Q2 2016 filing shows 1 increased, 1 reduced and 1 closed positions. The largest sale was Nevro, an estimated $5.27M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM Asset Management added most to Chiasma in Q2 2016, an estimated $241K increase.
  • MPM Asset Management's biggest Q2 2016 reduction was Nevro, cutting an estimated $5.27M.
  • MPM Asset Management fully exited Avalo Therapeutics in Q2 2016, selling an estimated $2.22M.
  • MPM Asset Management's ten largest holdings make up 100% of its $308M portfolio in Q2 2016.
  • MPM Asset Management opened 0 new positions and closed 1 in Q2 2016.
  • MPM Asset Management's portfolio value fell 4.5% quarter-over-quarter to $308M.

Based on MPM Asset Management's 13F filing for Q2 2016, filed 8 Aug 2016.